JHS Svendgaard Laboratories
JHS NSE
JHS Svendgaard Laboratories
Consumer GoodsNSE: JHS BSE: 532771 Personal Care
Key Fundamentals
MicrocapPersonal CareConsumer GoodsMarket Cap
₹71.93 Cr
Volatility
Moderate
P/E Ratio
-36.9
EBITDA
₹2.61 Cr
Return on Equity
-11.43%
Debt to Equity
0.09
Book Value
₹19.98
52W High
₹13.9
52W Low
₹6.26
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Stock is trading at 0.42 times its book value
Weaknesses
6- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.18% over past five years.
- Promoter holding is low: 33.8%
- Company has a low return on equity of -4.75% over last 3 years.
- Earnings include an other income of Rs.2.55 Cr.
- Promoter holding has decreased over last 3 years: -8.38%
Growth Rate
Revenue Growth
7.15% higher than
3Y
Net Income Growth
-86.29% lower than
3Y
Cash Flow Change
43.57% higher than
3Y
ROE
378% higher than
3Y
ROCE
296% higher than
3Y
EBITDA Margin (Avg.)
-308% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.9 | 18.93 | 14.3 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 | 22.28 | 23.27 | 32.7 | 30.38 |
| Expenses | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 | 21.37 | 21.6 | 34.34 | 28.31 |
| Operating Profit | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 | 0.91 | 1.67 | -1.64 | 2.07 |
| OPM % | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.1% | -21.37% | 7.08% | 4.08% | 7.18% | -5.02% | 6.81% |
| Other Income | 0.41 | 0.2 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1 | 1.14 | 0.59 | 0.73 | 0.09 |
| Interest | 0.13 | 0.1 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 | 0.2 | 0.28 | 0.22 | 0.28 |
| Depreciation | 1.32 | 1.5 | 1.63 | 1.9 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 | 1.86 | 1.9 | 1.86 | 1.82 |
| PBT | -3.16 | -0.99 | 0.54 | 0.18 | 0.2 | -2.07 | -1.58 | -9.05 | 0.62 | -0.01 | 0.08 | -2.99 | 0.06 |
| Tax % | -18.35% | -26.26% | 100% | 516.67% | 415% | 398.07% | 15.82% | -23.09% | -69.35% | 1800% | -887.5% | 19.73% | -1716.67% |
| Net Profit | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 | -0.2 | 0.79 | -3.57 | 1.09 |
| EPS in Rs | -0.4 | -0.09 | 0 | -0.1 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 | -0.02 | 0.09 | -0.41 | 0.12 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 100 | 104 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 92 | 102 | 109 |
| Expenses | 59 | 93 | 92 | 126 | 124 | 137 | 99 | 87 | 94 | 72 | 96 | 99 | 106 |
| Operating Profit | -4 | 7 | 12 | 14 | 0 | 2 | 2 | -1 | -9 | -1 | -4 | 3 | 3 |
| OPM % | -7% | 7% | 11% | 10% | 0.1% | 1.2% | 1.9% | -1% | -11% | -1.3% | -4.4% | 2.6% | 2.8% |
| Other Income | -6 | -17 | 0 | 32 | 6 | 3 | 7 | 9 | -7 | 4 | 0 | 3 | 3 |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Depreciation | 12 | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 8 | 8 | 7 |
| PBT | -22 | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -13 | -2 | -3 |
| Tax % | 0% | 0% | -327% | 32% | -19% | -17% | -39% | 4000% | -24% | 18% | 58% | -16% | — |
| Net Profit | -22 | -22 | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -20 | -2 | -2 |
| EPS in Rs | -9.2 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -0.22 | -0.22 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 | 87 |
| Reserves | 96 | 63 | 90 | 113 | 116 | 117 | 124 | 121 | 95 | 91 | 87 | 87 |
| Borrowings | 19 | 3 | 2 | 2 | 7 | 9 | 7 | 6 | 3 | 5 | 6 | 15 |
| Other Liabilities | 33 | 19 | 19 | 32 | 39 | 55 | 33 | 30 | 52 | 22 | 25 | 26 |
| Total Liabilities | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 215 |
| Fixed Assets | 108 | 65 | 65 | 71 | 71 | 66 | 63 | 59 | 65 | 90 | 90 | 89 |
| CWIP | 0 | 1 | 1 | 1 | 5 | 7 | 9 | 20 | 9 | 1 | 0 | 4 |
| Investments | 0 | 0 | 1 | 18 | 10 | 6 | 2 | 4 | 3 | 3 | 4 | 5 |
| Other Assets | 63 | 57 | 89 | 118 | 137 | 163 | 154 | 140 | 152 | 102 | 110 | 117 |
| Total Assets | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 215 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 7 | -4 | -4 | 14 | -11 | 10 | 12 | -9 | 23 | -9 | -5 | -3 |
| Investing | 1 | 1 | -3 | -27 | -7 | -11 | -2 | -5 | 10 | -21 | -20 | -12 |
| Financing | -10 | 4 | 10 | 14 | 13 | 0 | 10 | -2 | -1 | 2 | 23 | 11 |
| Net Cash Flow | -1 | 2 | 3 | 0 | -5 | 0 | 20 | -16 | 32 | -28 | -2 | -3 |
| Free Cash Flow | 9 | -7 | -17 | 3 | -26 | 0 | 5 | -16 | 21 | -33 | -14 | -15 |
| CFO/OP | -189 | -58 | -33 | 119 | -10,000 | 595 | 650 | 1,051 | -257 | 1,001 | 122 | -77 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 | 60 |
| Inventory Days | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 | 85 |
| Days Payable | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 | 100 |
| Cash Conversion Cycle | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 | 45 |
| Working Capital Days | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 | 42 |
| ROCE % | -12% | -3% | 5% | 8% | 0% | 4% | 1% | 1% | -2% | -2% | -5% | -1% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view JHS Svendgaard Laboratories insights
65 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - JHS Svendgaard files Large Corporate disclosure; confirms not a large corporate, outstanding borrowing was 13.87 Cr on 31 March 2026. 30 Apr - JHS Svendgaard files Large Corporate disclosure; confirms not a large corporate, outstanding borrowing was 13.87 Cr on 31 March 2026.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - JHS Svendgaard files Large Corporate disclosure; confirms not a large corporate, outstanding borrowing was 13.87 Cr on 31 March 2026. 30 Apr - JHS Svendgaard files Large Corporate disclosure; confirms not a large corporate, outstanding borrowing was 13.87 Cr on 31 March 2026.
3
Announcement under Regulation 30 (LODR)-Change in RTA
27 Apr - JHS Svendgaard changed RTA from Alankit to Beetal, effective 27 April 2026. 27 Apr - JHS Svendgaard changed RTA from Alankit to Beetal, effective 27 April 2026.
4
Announcement under Regulation 30 (LODR)-Change in RTA
10h - JHS Svendgaard changed RTA from Alankit to Beetal, effective 27 April 2026. 10h - JHS Svendgaard changed RTA from Alankit to Beetal, effective 27 April 2026.
5
Announcement under Regulation 30 (LODR)-Change in RTA
15 Apr - RTA changed from Alankit Assignments to Beetal Financial; effective date to be intimated later. 15 Apr - RTA changed from Alankit Assignments to Beetal Financial; effective date to be intimated later.
Frequently Asked Questions about JHS Svendgaard Laboratories
What does JHS Svendgaard Laboratories Ltd do?
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of
oral and dental products for national and international brands[1]
Where is JHS Svendgaard Laboratories Ltd (JHS) listed?
JHS Svendgaard Laboratories Ltd trades as JHS on the NSE and under code 532771 on the BSE.
Which sector does JHS Svendgaard Laboratories Ltd belong to?
JHS Svendgaard Laboratories Ltd is classified under the Consumer Goods sector, in the Personal Care industry.
What is the market capitalisation of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd has a market capitalisation of ₹71.93 Cr, which places it in the Small Cap band.
What is the PE ratio of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd trades at a PE ratio of -36.90, against a book value of ₹19.98 per share.
What is the 52-week high and low of JHS Svendgaard Laboratories Ltd?
Over the last 52 weeks JHS Svendgaard Laboratories Ltd has traded between ₹6.26 and ₹13.9.
What is the Return on Equity (ROE) of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd reported a return on equity of -11.43%. Its debt-to-equity ratio is 0.09.
Company Information
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of oral and dental products for national and international brands[1]
Website svendgaard.com
CEO Mr. Nikhil Nanda
Employees 263
Listed 2006-10-21
Face Value ₹ 10
Issued Size 8,56,03,966
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JHS.md for JHS Svendgaard Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.